GSK3B and neoplasm: One recent study showed that the simultaneous inhibition of tumor glycolysis (through cycling fasting) and OXPHOS (through metformin) produces synergistic and long-lasting anticancer effects in tumor cell lines and tumor-bearing mice, which are mediated through a potent activation of the PP2A-GSK3β tumor suppressor axis14.